Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Benzinga Newsdesk www.benzinga.com Neutral 51.0%

Neg 0% Neu 51% Pos 0%

Raymond James analyst Sean McCutcheon initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $56.